{'fraction_non_alphanumeric': 0.030107526881720432, 'fraction_numerical': 0.015053763440860216, 'mean_word_length': 4.782608695652174, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Insulin-like growth factor I concentration in dogs with inflammatory and neoplastic liver diseases.

Liver diseases are known to influence the serum concentration of insulin-like growth factor I (IGF-I) in humans, but such an effect has rarely been investigated in dogs. The aim of this study was to investigate serum IGF-I concentrations in dogs with primary liver diseases, in comparison with levels in healthy dogs and dogs with non-hepatic diseases. For this purpose, IGF-I serum concentrations were measured (DSL-5600 kit) in 36 dogs with various liver diseases and compared with 22 healthy controls and 20 dogs with non-hepatic diseases. The results showed that dogs with liver diseases had significantly lower IGF-I serum concentrations (P < 0.001) than clinical healthy dogs or dogs with non-hepatic diseases. But the results also indicate that the aetiology of liver disease has no influence on IGF-I serum concentration.